Treating NASH (nonalcoholic steatohepatitis) starts with weight loss, which remains the single most effective intervention. Losing at least 10% of your body weight resolves NASH in about 90% of people and reverses liver scarring in nearly half. Beyond lifestyle changes, the first medication specifically approved for NASH reached the market in 2024, and several more are in late-stage trials. The condition is serious enough to warrant active treatment: over an eight-year period, roughly 39% of people with fatty liver disease progress to cirrhosis.
What NASH Does to Your Liver
NASH is an advanced form of fatty liver disease. While simple fatty liver (steatosis) involves fat buildup without significant damage, NASH adds two dangerous elements: inflammation and ballooning of liver cells. This combination, confirmed through liver biopsy, is what separates NASH from its milder counterpart and makes it a progressive disease capable of causing permanent scarring.
That scarring, called fibrosis, is staged from 0 to 4. Stages 1 and 2 represent mild to moderate scarring. Stage 3 is advanced fibrosis, and stage 4 is cirrhosis. Your fibrosis stage is the strongest predictor of long-term outcomes, which is why most treatments aim to halt or reverse it. Among people who reach compensated cirrhosis (stage 4 without organ failure), 45% develop decompensated cirrhosis over the following eight years, a life-threatening condition that often requires a liver transplant.
Weight Loss: The Most Proven Treatment
No drug currently matches the effect of sustained weight loss on NASH. The thresholds are well established and worth knowing, because each level of weight loss unlocks progressively greater benefits.
- 5% body weight loss reduces liver fat by about 25% and improves your overall disease activity score.
- 7 to 10% body weight loss begins to improve both inflammation and fibrosis.
- 10% or more body weight loss resolves NASH in 90% of people and reverses fibrosis in 45%.
The challenge is obvious: losing 10% of your body weight and keeping it off is difficult. Most clinical trials using diet and exercise alone see only a fraction of participants reaching that goal. That reality is part of what drives the search for effective medications. Still, any weight loss helps. If you’re starting at a higher weight, even a 5% reduction produces measurable improvements in liver fat and inflammation.
No single diet has proven superior for NASH, but Mediterranean-style eating patterns (rich in olive oil, fish, vegetables, nuts, and whole grains) consistently show benefits in liver fat reduction. The key factor is sustained caloric deficit rather than any specific macronutrient ratio. Exercise adds independent benefit even without weight loss by reducing liver fat and improving insulin sensitivity. Both aerobic exercise and resistance training are effective.
Rezdiffra: The First Approved NASH Medication
In March 2024, the FDA approved resmetirom (brand name Rezdiffra), the first drug specifically designed to treat NASH with moderate to advanced fibrosis (stages 2 and 3). It works by activating a thyroid hormone receptor in the liver, which speeds up fat metabolism and reduces inflammation.
In its phase 3 trial, about 26% of patients taking the lower dose achieved NASH resolution without worsening fibrosis, compared to 9 to 13% on placebo. For fibrosis improvement specifically, 23% of patients on the lower dose saw their scarring improve without their NASH getting worse, compared to 13 to 15% on placebo. These numbers are modest on their own, but they represent a genuine treatment effect in a disease that previously had no approved pharmacological option.
Rezdiffra is taken once daily as a pill, with the dose based on body weight. It’s approved for use alongside diet and exercise, not as a replacement. The drug is intended for people with confirmed NASH and significant fibrosis, not for everyone with fatty liver.
Vitamin E and Pioglitazone
Before Rezdiffra, two off-label treatments were the main pharmacological options. Vitamin E at 800 IU daily has shown meaningful improvement in liver inflammation and fat content in adults with NASH who do not have diabetes. A landmark trial of 247 adults found it significantly improved disease activity compared to placebo over 96 weeks. The catch: the trial specifically excluded people with diabetes, so its benefit in that group remains unclear. There are also concerns about long-term high-dose vitamin E use, including a small increased risk of prostate cancer and hemorrhagic stroke.
Pioglitazone, a diabetes medication that improves insulin sensitivity, has also shown benefit in NASH, including in people with type 2 diabetes. It was tested at 30 mg daily in the same trial. Side effects include weight gain and fluid retention, which limits its appeal for many patients.
GLP-1 Drugs and the Next Wave of Treatment
The medications generating the most excitement for NASH treatment are the GLP-1 receptor agonists and related drugs already widely used for diabetes and weight loss. Tirzepatide, which targets two gut hormone receptors simultaneously, produced striking results in a phase 2 trial published in the New England Journal of Medicine. Among participants taking the highest dose, 62% achieved NASH resolution without worsening fibrosis, compared to 10% on placebo. Even the lowest dose resolved NASH in 44% of participants.
These numbers far exceed what Rezdiffra achieved, though it’s worth noting the trials enrolled different patient populations and used different designs. Tirzepatide is not yet approved specifically for NASH, but its ability to drive substantial weight loss (addressing the root cause) while also appearing to have direct liver benefits makes it a strong candidate for future approval. Semaglutide, the active ingredient in Ozempic and Wegovy, has shown similar promise in earlier trials and is being studied in larger confirmatory studies.
Bariatric Surgery
For people with obesity who haven’t achieved sufficient weight loss through other means, bariatric surgery offers the most dramatic results. Long-term follow-up data show that up to 84% of patients achieve NASH resolution within five years after surgery. The weight loss is typically large enough (well beyond 10% of body weight) to push most patients past every meaningful threshold for liver improvement.
Surgery is generally considered for people with a BMI of 40 or higher, or 35 and above with obesity-related health conditions like NASH. It’s not a first-line treatment, but for the right candidates, it can effectively cure the disease.
Tracking Your Progress Without a Biopsy
Liver biopsy remains the gold standard for diagnosing NASH, but it’s invasive and impractical for regular monitoring. Most doctors now use a non-invasive ultrasound-based test called transient elastography (often by the brand name FibroScan) to track liver stiffness and fat content over time.
The test produces two numbers. Liver stiffness, measured in kilopascals (kPa), estimates fibrosis stage. A reading below 6.5 kPa rules out advanced fibrosis with over 91% certainty. Readings around 11 to 12 kPa suggest stage 3 fibrosis, and values above 14.9 kPa point toward cirrhosis. The second number, called CAP, measures liver fat in decibels per meter. Values below 274 dB/m suggest minimal fat, while readings above 340 dB/m indicate severe steatosis.
These numbers give you and your doctor a way to monitor whether treatment is working without repeated biopsies. Improving your liver stiffness score over 6 to 12 months is a concrete sign that fibrosis is stabilizing or reversing.
Coffee and Other Lifestyle Factors
Drinking 2 to 4 cups of coffee daily is associated with slower fibrosis progression, lower liver enzyme levels, and reduced risk of liver cancer. Caffeine blocks specific receptors in the liver that drive inflammation and scarring. But coffee also contains compounds that work independently of caffeine: one shunts cholesterol byproducts toward bile acids rather than toxic metabolites, and this effect appears in both caffeinated and decaffeinated coffee. If you already drink coffee, there’s good reason to continue. If you don’t, this alone isn’t a reason to start, but it’s a low-risk addition to a broader treatment plan.
Alcohol should be minimized or eliminated entirely. Even moderate drinking accelerates liver damage in people who already have NASH. Fructose-heavy diets, particularly from sugar-sweetened beverages, are independently linked to worsening liver fat and should be reduced.